The startup has developed a portable PhotonUVC device that emits low-dose UVC light to treat corneal infections in humans and pets, effectively deactivating pathogens without causing harm or pain. This device can deliver over 100 treatments on a single charge and complements conventional antibiotic drops, providing a first-line option for suspected corneal infections without contributing to microbial resistance.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Corneal infections are a leading cause of blindness in both humans and animals, often requiring prolonged treatment with antibiotic drops and posing a risk of microbial resistance. Current treatment options may also be limited by challenges in administration and patient compliance.
Solution
Photon Therapeutics offers the PhotonUVC Vet, a non-contact device that delivers low-dose UVC light to deactivate infectious organisms on the cornea in just five seconds. This empiric treatment approach eliminates the risk of microbial resistance and is safe for host tissues. The device can be either hand-held or slit-lamp mounted, providing ease of use during initial consultations. By directly targeting the DNA of microorganisms, the PhotonUVC Vet offers a rapid and effective first-line treatment option for suspected corneal infections, complementing or replacing traditional antibiotic therapies.
Target Audience
The primary target audience includes veterinary ophthalmologists and general practice veterinarians seeking a fast, effective, and safe treatment for corneal infections in animals.
Features
- Non-contact UVC light delivery to minimize the risk of cross-contamination
- Broad-spectrum antimicrobial effect, targeting the DNA of bacteria, fungi, and viruses
- Rapid 5-second treatment time, improving clinic workflow and patient compliance
- No microbial resistance, providing a sustainable alternative to antibiotics
- Safe for host tissues at the patented wavelength and low-dose application
- Portable and rechargeable, enabling over 100 treatments per charge
- Can be hand-held or slit-lamp mounted for flexible use in various clinical settings